Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Dimethyl fumarate for multiple sclerosis.
Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis.
Long-term efficacy and safety of transanal irrigation in multiple sclerosis.
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study.
Neuroimmunology: Phase II trial demonstrates efficacy of erythropoietin in optic neuritis.
Sleep and Cognitive Function in Multiple Sclerosis.
Secondary Progressive Multiple Sclerosis: Definition and Measurement.
Validation of the Brazilian version of the neurological fatigue index for multiple sclerosis.
Interferon beta-1b
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
JC polyomavirus mutants escape antibody-mediated neutralization.
Extraocular Source of Oligodendrocytes Contribute to Retinal Myelination and Optokinetic Responses in Zebrafish.
Episode 14 with Professor Gavin Giovannoni on the Epstein-Barr Virus (EBV).
JOINT CONGRESS OF EUROPEAN NEUROLOGY
Association between beta-interferon exposure and hospital events in multiple sclerosis.
FOCIS Advanced Course in Basic and Clinical Immunology
Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination.
AAN: Annual Meeting On Demand Encore: Treatment Optimization for Relapsing MS
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.
Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
Effirma, Synthetic Biologics
Bilateral optic neuritis in a patient with Behçet's disease who respond to therapeutic plasma exchange.
Contribution of different relapse phenotypes to disability in multiple sclerosis.

Pages